Compare Adaptive Biotechnologies Corp (ADPT) vs Paycom Software Inc (PAYC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Paycom Software Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.03 (market cap $3.33B), while Paycom Software Inc trades at $138.3 (market cap $6.70B). The key difference: Paycom Software Inc is far larger — about 2× Adaptive Biotechnologies Corp's market cap, and Paycom Software Inc pays a 1.04% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PAYC | |
|---|---|---|
Market Cap | $3.33B | $6.70B |
Sector | Health | Technology |
52-Week High | $22.37 | $238.80 |
52-Week Low | $10.24 | $113.59 |
Enterprise Value | $3.19B | $7.31B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Paycom Software (PAYC) trades at $143.78, up 3.28% on the day, with a bullish technical signal and strong fundamentals including a 22.44% net income margin and 37.15% ROE. Recent earnings beat expectations in Q1 2026, and the company maintains robust cash flow from operations of $678.9 million in 2025. Analyst consensus is mixed with a $151 price target, while recent news highlights its value stock appeal and industry awards.
The outlook for PAYC is positive with solid revenue growth and profitability, though risks include competitive pressures and market volatility. The stock's current valuation metrics, such as a P/E of 16.19, suggest room for upside if earnings momentum continues, but investors should weigh execution risks against the bullish analyst sentiment and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
